Advertisement
YOU ARE HERE: LAT HomeCollectionsSmithkline Beecham Corp
IN THE NEWS

Smithkline Beecham Corp

FEATURED ARTICLES
NEWS
September 30, 1997 | MARCIDA DODSON, TIMES STAFF WRITER
A Mission Viejo weight-loss clinic, its doctor and makers of the diet regimen fen-phen have been named in a class-action lawsuit by a woman who alleges she has heart problems because of the drugs. The suit is believed to be the first of its kind to be filed in Orange County over the effects of the once-popular diet drugs. Fenfluramine, one of the two drugs used in combination for weight loss, was pulled off the market by the U.S Food and Drug Administration earlier this month.
ARTICLES BY DATE
NEWS
August 10, 1998 | MARK FINEMAN, TIMES STAFF WRITER
When Franklin Sotolongo injected himself with the vial of experimental liquid that day in 1985, it was one of the most emotional moments of his life. Sotolongo was leading a small team of Cuban scientists struggling to save their nation from an epidemic of group B meningitis. Hundreds of children were dying, and there was neither a cure nor a vaccine--not only on their isolated Communist island, but anywhere on the globe.
Advertisement
BUSINESS
July 23, 1997 | From Bloomberg News
Five big drug makers on Tuesday reported higher second-quarter earnings, though the gains were eclipsed by news that SmithKline Beecham Corp. is ready to enter the lucrative but crowded market for cholesterol-lowering drugs. Warner-Lambert Co. and Schering-Plough Corp. beat expectations, while Bristol-Myers Squibb Co. and American Home Products Corp. matched estimates. Britain's SmithKline had lower-than-expected profit, as the pound's strength offset rising drug sales.
BUSINESS
January 31, 1998 | JAMES F. PELTZ, TIMES STAFF WRITER
Giant drug makers Glaxo Wellcome and SmithKline Beecham unveiled a stunning merger proposal late Friday that would create the world's largest pharmaceutical company and would likely be the biggest corporate marriage in history. A deal between the two British companies would send repercussions through the worldwide health-care market, from major hospital chains to consumers' corner drugstores.
NEWS
August 10, 1998 | MARK FINEMAN, TIMES STAFF WRITER
When Franklin Sotolongo injected himself with the vial of experimental liquid that day in 1985, it was one of the most emotional moments of his life. Sotolongo was leading a small team of Cuban scientists struggling to save their nation from an epidemic of group B meningitis. Hundreds of children were dying, and there was neither a cure nor a vaccine--not only on their isolated Communist island, but anywhere on the globe.
BUSINESS
January 31, 1998 | JAMES F. PELTZ, TIMES STAFF WRITER
Giant drug makers Glaxo Wellcome and SmithKline Beecham unveiled a stunning merger proposal late Friday that would create the world's largest pharmaceutical company and would likely be the biggest corporate marriage in history. A deal between the two British companies would send repercussions through the worldwide health-care market, from major hospital chains to consumers' corner drugstores.
BUSINESS
November 9, 1993 | From Times Staff and Wire Reports
Drug Company to Offer Tagamet Rebate: SmithKline Beecham said it will offer cash to Americans who buy the ulcer treatment, one of the world's biggest-selling drugs. The decision to place counter displays in 50,000 pharmacies takes name-brand drug price competition into drugstores for the first time, and analysts called the move a "revolutionary" step. Drug makers are scrambling to compete amid growing pressure to cut prices.
NEWS
January 24, 1990 | From Times Staff and Wire Reports
Attorneys for Bolar Pharmaceutical Co., a New York firm seeking to keep its generic blood-pressure medication on the market, said in letters released by a House subcommittee that the company gave them phony test reports to show federal regulators. Bolar was already under federal scrutiny because of allegations that it used false documents to demonstrate to the Food and Drug Administration that its product is equivalent to Dyazide, made by Smithkline Beecham.
BUSINESS
December 22, 1998 | From Bloomberg News
Careside Inc., a Culver City-based company developing a blood-testing system that would provide results within 15 minutes, said Monday that it will seek to raise as much as $31.6 million through an initial public offering. Careside was founded in 1996 by Chief Executive Vickery Stoughton, Executive Vice President Thomas Grove and director Philip Smith to acquire technology developed by SmithKline Beecham Clinical Laboratories Inc. Careside's founders control about 20% of the company.
BUSINESS
August 28, 1991 | From Associated Press
Bolar Pharmaceutical Co. said Tuesday that it agreed to pay SmithKline Beecham Corp. $40 million to settle a lawsuit accusing Bolar of lying to get government approval for a generic version of a hypertension drug. The settlement is the latest in a series of actions involving troubled Bolar, which in March pleaded guilty to federal criminal charges for selling adulterated and mislabeled generic drugs and was fined $10 million.
NEWS
September 30, 1997 | MARCIDA DODSON, TIMES STAFF WRITER
A Mission Viejo weight-loss clinic, its doctor and makers of the diet regimen fen-phen have been named in a class-action lawsuit by a woman who alleges she has heart problems because of the drugs. The suit is believed to be the first of its kind to be filed in Orange County over the effects of the once-popular diet drugs. Fenfluramine, one of the two drugs used in combination for weight loss, was pulled off the market by the U.S Food and Drug Administration earlier this month.
BUSINESS
July 23, 1997 | From Bloomberg News
Five big drug makers on Tuesday reported higher second-quarter earnings, though the gains were eclipsed by news that SmithKline Beecham Corp. is ready to enter the lucrative but crowded market for cholesterol-lowering drugs. Warner-Lambert Co. and Schering-Plough Corp. beat expectations, while Bristol-Myers Squibb Co. and American Home Products Corp. matched estimates. Britain's SmithKline had lower-than-expected profit, as the pound's strength offset rising drug sales.
BUSINESS
November 9, 1993 | From Times Staff and Wire Reports
Drug Company to Offer Tagamet Rebate: SmithKline Beecham said it will offer cash to Americans who buy the ulcer treatment, one of the world's biggest-selling drugs. The decision to place counter displays in 50,000 pharmacies takes name-brand drug price competition into drugstores for the first time, and analysts called the move a "revolutionary" step. Drug makers are scrambling to compete amid growing pressure to cut prices.
NEWS
January 24, 1990 | From Times Staff and Wire Reports
Attorneys for Bolar Pharmaceutical Co., a New York firm seeking to keep its generic blood-pressure medication on the market, said in letters released by a House subcommittee that the company gave them phony test reports to show federal regulators. Bolar was already under federal scrutiny because of allegations that it used false documents to demonstrate to the Food and Drug Administration that its product is equivalent to Dyazide, made by Smithkline Beecham.
BUSINESS
February 9, 1996 | Times Wire Services
New vaccines for preventing whooping cough in infants should be approved for use in the United States, according to an editorial in the New England Journal of Medicine. The authors commented on two studies published in the journal's Feb. 8 issue that found that vaccines made by SmithKline Beecham, Chiron Corp. and Connaught Laboratories were effective for preventing whooping cough in infants and caused fewer side effects than current vaccines.
Los Angeles Times Articles
|